Arkolith/Insider Trading/EVLO/Form 4

Gill Simba

President & CEO, DirectorEvelo Biosciences, Inc. (EVLO) · full profile →Form 4 · filed Nov 8, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$57
Net Open-Market Flow
-$57
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 8, 2023Sell(S)172$0.33$5718K
Nov 7, 2023Option exercise(M)1K——18K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Nov 7, 2023Option exercise(M)1K—$015K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001694665-23-000176) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML